These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12116607)

  • 21. Hormone replacement therapy in women with breast cancer.
    Braendle W
    Anticancer Res; 1998; 18(3C):2253-5. PubMed ID: 9703796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.
    Mohandas B; Mehta JL
    Curr Opin Cardiol; 2007 Sep; 22(5):434-42. PubMed ID: 17762545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response.
    Hartsfield CL; Connelly MT; Newton KM; Andrade SE; Wei F; Buist DS
    J Natl Cancer Inst Monogr; 2005; (35):113-5. PubMed ID: 16287896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular effects of estrogen replacement therapy.
    Chae CU; Manson JE
    Adv Intern Med; 2001; 47():47-88. PubMed ID: 11795080
    [No Abstract]   [Full Text] [Related]  

  • 28. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
    Runowicz CD
    Health News; 2003 Apr; 9(4):1-2. PubMed ID: 12710388
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of estrogens, selective estrogen receptor modulators and phytoestrogens in cardiovascular protection.
    Herrington D
    Can J Cardiol; 2000 Aug; 16 Suppl E():5E-9E. PubMed ID: 10906617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmenopausal estrogen and cardiovascular disease.
    Stampfer MJ; Grodstein F; Bechtel S
    Contemp Intern Med; 1994 Sep; 6(9):47-56, 59. PubMed ID: 10150308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KEEPS: The Kronos Early Estrogen Prevention Study.
    Harman SM; Brinton EA; Cedars M; Lobo R; Manson JE; Merriam GR; Miller VM; Naftolin F; Santoro N
    Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of raloxifene: the arterial and venous systems.
    Blumenthal RS; Baranowski B; Dowsett SA
    Am Heart J; 2004 May; 147(5):783-9. PubMed ID: 15131531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches to the endocrine prevention and treatment of breast cancer.
    Howell A; Howell SJ; Evans DG
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S39-44. PubMed ID: 12819938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The case for postmenopausal hormone therapy.
    Speroff L
    Hosp Pract (1995); 1996 Feb; 31(2):75-89. PubMed ID: 8592021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.